Precision Biosciences Inc
DTIL Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$6.64
KIRA · Stoqly’s AI analyst, in plain words
- Precision Biosciences Inc had $34.3M of revenue in fiscal 2025, down 50.1% on the year before. Over five years, revenue changed +7.1% a year on average.
- Its operating margin was −152.2%, down 114.1 pts: of every 100 in sales, about −152 is left after running the business.
- Precision Biosciences Inc lost $45.7M in fiscal 2025.
- Free cash flow was −$65.9M in fiscal 2025, −192.4% of revenue.
Market cap
$172M
P/E
—
Revenue
$34.3M
Net income
−$45.7M
Free cash flow
−$65.9M
Operating margin
−152.2%
Precision Biosciences Inc in 30 seconds · fiscal 2025
Are sales growing?
−50.1%
No. Sales fell 50.1% last year.
Does it make a profit?
−133.4%
No. It lost money last year.
Does profit turn into cash?
−192.4%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Precision Biosciences Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- PRECISION BIOSCIENCES INC
- CIK
- 0001357874
Precision Biosciences Inc · DTIL
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $116M | $25.1M | $48.7M | $68.7M | $34.3M |
| Revenue growth | 375.7% | −78.3% | 94.1% | 41.0% | −50.1% |
| Operating margin | −34.1% | −248.3% | −89.8% | −38.1% | −152.2% |
| Net income | −$30.6M | −$112M | −$61.3M | $7.2M | −$45.7M |
| Net margin | −26.5% | −444.8% | −125.8% | 10.4% | −133.4% |
| Diluted EPS | −$0.52 | −$38.10 | −$15.96 | $1.04 | −$3.56 |
| Cash | |||||
| Cash from operations | −$10.9M | −$45.8M | −$84.1M | −$58.4M | −$65.8M |
| Capital expenditure | $5.1M | $3.3M | $2.0M | $0.3M | $0.1M |
| Free cash flow | −$15.9M | −$49.1M | −$86.1M | −$58.7M | −$65.9M |
| FCF margin | −13.8% | −195.5% | −176.6% | −85.4% | −192.4% |
| Share count change | 12.8% | −95.0% | 31.1% | 79.2% | 86.3% |
| Debt and strength | |||||
| Cash and short-term investments | $144M | $190M | $117M | $86.3M | $116M |
| Debt incl. finance leases | $2.5M | $22.2M | — | — | — |
| Shareholders' equity | $91.2M | $60.4M | $18.9M | $56.4M | $92.2M |
| Current ratio | 4.5x | 3.3x | 2.7x | 6.3x | 13.3x |
| Interest coverage | −298.3x | −56.1x | −19.6x | −14.7x | −36.7x |
| Returns and quality | |||||
| Return on equity | −45.1% | −147.3% | −154.7% | 19.0% | −61.5% |
| Return on tangible equity | −34.3% | −187.0% | −332.2% | 12.9% | −50.2% |
| Piotroski F-score | 4 | 2 | 2 | 4 | 1 |
| Altman Z'' | −1.4 | −3.4 | −8.1 | −8.2 | −7.2 |
Insiders bought, 12 months
$0.1M
3 insiders
Insiders sold, 12 months
$0.5M
4 insiders
Of sales under plans
100%
$0.5M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Precision Biosciences Inc · DTIL
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $6.64 a share, the company is worth $172M.
Source: SEC EDGAR XBRL filings (CIK 0001357874). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.